TCV vaccines comparison
ExportBharat Biotech
Biological E
Zydus Lifesciences
SK Bioscience
BioMed Ltd
Incepta Pharmaceuticals
PT Bio Farma (Persero)
Central Drugs Standard Control Organization (CDSCO), India
Central Drugs Standard Control Organization (CDSCO), India
Central Drugs Standard Control Organization (CDSCO), India
Ministry of Food and Drug Safety (MFDS), Republic of Korea
Central Drugs Standard Control Organization (CDSCO), India
DGDA, Bangladesh
Badan POM / BPOM, Indonesia
2013
2020
2017
2022 (export licence only)
2008
2025
2023
2017 (22 December 2017)
2020 (4 December 2020)
2024 (21 October 2024)
2024 (21 February 2024)
No
No
No
Vi–TT conjugate
Vi–CRM197 conjugate
Vi–TT conjugate
Vi–DT conjugate
Vi–TT conjugate
Vi–DT conjugate
Vi–DT conjugate
25 µg Vi capsular polysaccharide per 0.5 mL dose
25 µg Vi capsular polysaccharide per 0.5 mL dose
25 µg Vi capsular polysaccharide per 0.5 mL dose
25 µg Vi capsular polysaccharide per 0.5 mL dose
5 µg Vi capsular polysaccharide per 0.5 mL dose
25 µg Vi capsular polysaccharide per 0.5 mL dose
25 µg Vi capsular polysaccharide per 0.5 mL dose
N/A
Bacterial fermentation followed by chemical conjugation to CRM197
Bacterial fermentation followed by chemical conjugation to tetanus toxoid
Bacterial fermentation followed by chemical conjugation to diphtheria toxoid
Bacterial fermentation followed by chemical conjugation to tetanus toxoid
Bacterial fermentation followed by chemical conjugation to diphtheria toxoid
Bacterial fermentation followed by chemical conjugation to diphtheria toxoid
No
No
No
No
No
No
No
None in single-dose vial; 2-phenoxyethanol, 5 mg in 5-dose vial
2-phenoxyethanol, 5 mg/dose in both single-dose and 5-dose presentations
2-phenoxyethanol, 2.5 mg/dose
2-phenoxyethanol, 5 mg/dose
Information not available
Information not available
2-phenoxyethanol, 5 mg/dose
Not required (liquid, ready to use)
Not required (liquid, ready to use)
Not required (liquid, ready to use)
Not required (liquid, ready to use)
Not required (liquid, ready to use)
Not required (liquid, ready to use)
Not required (liquid, ready to use)
Liquid, ready to use
Liquid, ready to use
Liquid, ready to use
Liquid, ready to use
Liquid, ready to use
Liquid, ready to use
Liquid, ready to use
0.5 mL single-dose vial; 2.5 mL 5-dose vial
0.5 mL single-dose vial; 2.5 mL 5-dose vial
2.5 mL 5-dose vial
2.5 mL 5-dose vial
0.5 mL single-dose vial; 0.5 mL single-dose PFS
0.5 mL single-dose PFS
2.5 mL 5-dose vial; 5 mL 10-dose vial
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
Intramuscular
36 months
36 months
36 months
24 months
36 months
Information not available
24 months
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
2–8 °C
VVM30
VVM30
VVM30
VVM30
Information not available
Information not available
Information not available
14.45 cm³/dose, single-dose; 2.9 cm³/dose, 5-dose
14.7 cm³/dose, single-dose; 2.9 cm³/dose, 5-dose
2.62 cm³/dose
3.05 cm³/dose
Information not available
Information not available
Information not available
1 intramuscular dose of 0.5 mL
1 intramuscular dose of 0.5 mL
1 intramuscular dose of 0.5 mL
1 intramuscular dose of 0.5 mL
1 intramuscular dose of 0.5 mL
1 intramuscular dose of 0.5 mL
1 intramuscular dose of 0.5 mL
On the basis of standardized immunobridging criteria, WHO considers licensed TCVs interchangeable for programmatic use. Any recommended TCV may be used for the primary or booster dose.
On the basis of standardized immunobridging criteria, WHO considers licensed TCVs interchangeable for programmatic use. Any recommended TCV may be used for the primary or booster dose.
On the basis of standardized immunobridging criteria, WHO considers licensed TCVs interchangeable for programmatic use. Any recommended TCV may be used for the primary or booster dose.
On the basis of standardized immunobridging criteria, WHO considers licensed TCVs interchangeable for programmatic use. Any recommended TCV may be used for the primary or booster dose.
Information not available
Information not available
Information not available
No product-specific booster schedule applies. WHO recommends that decisions on a booster dose consider incidence, evidence of waning, age at primary vaccination, case fatality, antimicrobial resistance, cost-effectiveness and programme feasibility. Where a booster is used, a minimum interval of 1 year after the primary dose is recommended.
No product-specific booster schedule applies. WHO recommends that decisions on a booster dose consider incidence, evidence of waning, age at primary vaccination, case fatality, antimicrobial resistance, cost-effectiveness and programme feasibility. Where a booster is used, a minimum interval of 1 year after the primary dose is recommended.
No product-specific booster schedule applies. WHO recommends that decisions on a booster dose consider incidence, evidence of waning, age at primary vaccination, case fatality, antimicrobial resistance, cost-effectiveness and programme feasibility. Where a booster is used, a minimum interval of 1 year after the primary dose is recommended.
No product-specific booster schedule applies. WHO recommends that decisions on a booster dose consider incidence, evidence of waning, age at primary vaccination, case fatality, antimicrobial resistance, cost-effectiveness and programme feasibility. Where a booster is used, a minimum interval of 1 year after the primary dose is recommended.
No product-specific booster schedule applies. WHO recommends that decisions on a booster dose consider incidence, evidence of waning, age at primary vaccination, case fatality, antimicrobial resistance, cost-effectiveness and programme feasibility. Where a booster is used, a minimum interval of 1 year after the primary dose is recommended.
No product-specific booster schedule applies. WHO recommends that decisions on a booster dose consider incidence, evidence of waning, age at primary vaccination, case fatality, antimicrobial resistance, cost-effectiveness and programme feasibility. Where a booster is used, a minimum interval of 1 year after the primary dose is recommended.
No product-specific booster schedule applies. WHO recommends that decisions on a booster dose consider incidence, evidence of waning, age at primary vaccination, case fatality, antimicrobial resistance, cost-effectiveness and programme feasibility. Where a booster is used, a minimum interval of 1 year after the primary dose is recommended.
TCVs have a favourable safety profile. Available evidence indicates that repeat or booster dosing is well tolerated, with no increase in serious adverse events and reactogenicity similar to primary vaccination. No product-specific safety signal has been identified.
TCVs have a favourable safety profile. Available evidence indicates that repeat or booster dosing is well tolerated, with no increase in serious adverse events and reactogenicity similar to primary vaccination. No product-specific safety signal has been identified.
TCVs have a favourable safety profile. Available evidence indicates that repeat or booster dosing is well tolerated, with no increase in serious adverse events and reactogenicity similar to primary vaccination. No product-specific safety signal has been identified.
TCVs have a favourable safety profile. Available evidence indicates that repeat or booster dosing is well tolerated, with no increase in serious adverse events and reactogenicity similar to primary vaccination. No product-specific safety signal has been identified.
TCVs have a favourable safety profile. Available evidence indicates that repeat or booster dosing is well tolerated, with no increase in serious adverse events and reactogenicity similar to primary vaccination. No product-specific safety signal has been identified.
TCVs have a favourable safety profile. Available evidence indicates that repeat or booster dosing is well tolerated, with no increase in serious adverse events and reactogenicity similar to primary vaccination. No product-specific safety signal has been identified.
TCVs have a favourable safety profile. Available evidence indicates that repeat or booster dosing is well tolerated, with no increase in serious adverse events and reactogenicity similar to primary vaccination. No product-specific safety signal has been identified.
Yes
Yes
Yes
Not available for UNICEF procurement
No
No
No
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/typhoid-conjugate-vaccine-tcv-price-data - https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/typhoid-conjugate-vaccine-tcv-price-data - https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/typhoid-conjugate-vaccine-tcv-price-data - https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/typhoid-conjugate-vaccine-tcv-price-data - https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/typhoid-conjugate-vaccine-tcv-price-data - https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/typhoid-conjugate-vaccine-tcv-price-data - https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/typhoid-conjugate-vaccine-tcv-price-data - https://www.paho.org/en/documents/vaccine-prices-revolving-fund-2026
Vaccine price ranges by product, procurement mechanism and income group as reported through the WHO/UNICEF JRF can be found at https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data
[1] World Health Organization (2026). WHO Prequalification of Medical Products: Typbar-TCV, single-dose and 5-dose presentations. (https://extranet.who.int/prequal/vaccines/p/typbar-tcv and https://extranet.who.int/prequal/vaccines/p/typbar-tcv-0 , accessed 26 July 2026).
[2] World Health Organization (2019). Workshop on typhoid conjugate vaccine development and assessment, 25–26 November 2019: meeting report. (https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/typhoid-fever/tcv_meeting_report_workshop_25_26nov2019_final.pdf , accessed 26 July 2026).
[3] World Health Organization. WHO position paper on typhoid vaccines, August 2026. Wkly Epidemiol Rec. 2026;101:166–180 (https://www.who.int/publications/i/item/who-wer10132-166-180, accessed 22 September 2026).
[4] UNICEF Supply Division (2026). Typhoid conjugate vaccine (TCV) price data. April 2026 (https://www.unicef.org/supply/media/25331/file/Typhoid-vaccine-prices-14042026.pdf, accessed 26 July 2026).
[1] World Health Organization (2026). WHO Prequalification of Medical Products: TYPHIBEV®, single-dose and 5-dose presentations. (https://extranet.who.int/prequal/vaccines/p/typhibevr and https://extranet.who.int/prequal/vaccines/p/typhibevr-0 , accessed 26 July 2026).
[2] World Health Organization (2025). WHO Public Assessment Report: TYPHIBEV®, Biological E. Limited. (https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/FVP-P-379_408_Typhibev_Biological%20E._WHOPAR_2025.pdf, accessed 26 July 2026).
[3] World Health Organization. WHO position paper on typhoid vaccines, August 2026. Wkly Epidemiol Rec. 2026;101:166–180 (https://www.who.int/publications/i/item/who-wer10132-166-180, accessed 22 September 2026).
[4] UNICEF Supply Division (2026). Typhoid conjugate vaccine (TCV) price data. April 2026 (https://www.unicef.org/supply/media/25331/file/Typhoid-vaccine-prices-14042026.pdf, accessed 26 July 2026).
[1] World Health Organization (2026). WHO Prequalification of Medical Products: ZyVac® TCV. (https://extranet.who.int/prequal/vaccines/p/zyvacr-tcv, accessed 26 July 2026).
[2] World Health Organization (2024). WHO Public Assessment Report: ZyVac® TCV, Zydus Lifesciences Limited. (https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/fvp-p-442_typhoid_5doses_zydus_whopar-2024.pdf, accessed 26 July 2026).
[3] Kant R, Vashishtha VM, Kalra A, Sood A, Datta S (2024). The need and the issues related to new-generation typhoid conjugate vaccines in India. Indian J Med Res. (https://ijmr.org.in/the-need-the-issues-related-to-new-generation-typhoid-conjugate-vaccines-in-india, accessed 26 July 2026).
[4] World Health Organization. WHO position paper on typhoid vaccines, August 2026. Wkly Epidemiol Rec. 2026;101:166–180 (https://www.who.int/publications/i/item/who-wer10132-166-180, accessed 22 September 2026).
[5] UNICEF Supply Division (2026). Typhoid conjugate vaccine (TCV) price data. April 2026 (https://www.unicef.org/supply/media/25331/file/Typhoid-vaccine-prices-14042026.pdf, accessed 26 July 2026).
[1] World Health Organization (2026). WHO Prequalification of Medical Products: SKYTyphoid Multi Inj. (https://extranet.who.int/prequal/vaccines/p/skytyphoid-multi-inj, accessed 26 July 2026).
[2] World Health Organization (2024). WHO Public Assessment Report: SKYTyphoid Multi Inj., SK Bioscience Co., Ltd. (https://extranet.who.int/prequal/sites/default/files/vwa_vaccine/FVP_P_434_TCV_5dose_SK_WHOPAR-2024%20_0.pdf, accessed 26 July 2026).
[3] International Vaccine Institute (2022). New typhoid conjugate vaccine licensed in Korea. (https://www.ivi.int/new-typhoid-conjugate-vaccine-licensed-in-korea/, accessed 26 July 2026).
[4] World Health Organization. WHO position paper on typhoid vaccines, August 2026. Wkly Epidemiol Rec. 2026;101:166–180 (https://www.who.int/publications/i/item/who-wer10132-166-180, accessed 22 September 2026).
[5] UNICEF Supply Division (2026). Typhoid conjugate vaccine (TCV) price data. April 2026 (https://www.unicef.org/supply/media/25331/file/Typhoid-vaccine-prices-14042026.pdf, accessed 26 July 2026).
[1] BIO-MED (P) Ltd. (2024). Summary of Product Characteristics of Typhoid Vi Conjugate Vaccine I.P. (Peda Typh™). January 2024 (https://www.biomed.co.in/wp-content/uploads/2024/01/SmPC-Peda-Typh-I.P.pdf, accessed 26 July 2026).
[2] BIO-MED (P) Ltd. (2017). Summary of Product Characteristics of Typhoid Vi Conjugate Vaccine I.P. (Peda Typh™). May 2017 (https://www.biomed.co.in/wp-content/uploads/2017/12/SmPC-Peda-Typh.pdf, accessed 26 July 2026).
[3] BIO-MED (P) Ltd. Peda Typh™: Typhoid Vi Conjugate Vaccine I.P. (https://www.biomed.co.in/wp-content/uploads/2017/12/PPD-PEDA-TYPH.pdf, accessed 26 July 2026).
[1] Incepta Pharmaceuticals Ltd. Typhocon: Purified Typhoid Conjugate (Vi-DT) Vaccine INN [product leaflet]. (https://inceptavaccine.com/pdf/1781068818_pdoc_Typhocon%20Leaflet.pdf, accessed 26 July 2026).
[2] Incepta Pharmaceuticals Ltd. (2026). Vaccine Division of Incepta Pharmaceuticals Ltd. has organized a launch program of Typhocon®, the world’s only WHO-prequalified typhoid conjugate vaccine manufactured with a locally produced antigen. 14 May 2026 (https://inceptavaccine.com/news-events.php, accessed 26 July 2026).
[1] PT Bio Farma (Persero) (2023). Bio-TCV®: Typhoid Conjugate Vaccine [product leaflet]. (https://registrasiobat.pom.go.id/files/assesment-reports/01707107026.pdf, accessed 26 July 2026).
[2] Badan Pengawas Obat dan Makanan Republik Indonesia (2023). Public Assessment Report (Initial): BIO-TCV. 20 August 2023 (https://registrasiobat.pom.go.id/files/assesment-reports/8505827361724937915.pdf, accessed 26 July 2026).
[3] PT Bio Farma (Persero) (2026). Bio Farma Luncurkan BioTCV, Wujud Nyata Kolaborasi Terpadu Lintas Sektor untuk Memperkuat Kedaulatan Vaksin Nasional. 18 July 2026 (https://www.biofarma.co.id/id/announcement/detail/bio-farma-luncurkan-biotcv-wujud-nyata-kolaborasi-terpadu-lintas-sektor-untuk-memperkuat-kedaulatan-vaksin-nasional, accessed 26 July 2026).
Prices are UNICEF-awarded prices per dose under multi-year supply agreements using FCA Incoterms and exclude freight and programme delivery costs. Prices are subject to change.
Prices are UNICEF-awarded prices per dose under multi-year supply agreements using FCA Incoterms and exclude freight and programme delivery costs. Prices are subject to change.
Prices are UNICEF-awarded prices per dose under multi-year supply agreements using FCA Incoterms and exclude freight and programme delivery costs. Prices are subject to change.
Prices are UNICEF-awarded prices per dose under multi-year supply agreements using FCA Incoterms and exclude freight and programme delivery costs. Prices are subject to change.
Prices are UNICEF-awarded prices per dose under multi-year supply agreements using FCA Incoterms and exclude freight and programme delivery costs. Prices are subject to change.
Prices are UNICEF-awarded prices per dose under multi-year supply agreements using FCA Incoterms and exclude freight and programme delivery costs. Prices are subject to change.
Prices are UNICEF-awarded prices per dose under multi-year supply agreements using FCA Incoterms and exclude freight and programme delivery costs. Prices are subject to change.
